Bill Querbes
CSO Aera Therapeutics, Inc
Dr. Querbes is currently CSO at Aera. Prior to Aera, he served in several R&D roles including senior vice president of discovery and translational sciences at Tessera Therapeutics, vice president at AVROBIO and senior director at Synlogic, leading both research groups and development program teams. He spent 12 years at Alnylam Pharmaceuticals contributing to siRNA delivery platforms and the therapeutic pipeline. He led the discovery and early clinical development of GIVLAARI® (givosiran) for the treatment of hepatic porphyria, the first FDA approved GalNac conjugate RNAi therapeutic. He holds a B.S. from SUNY Geneseo and a Ph.D. from Brown University.
